Business
Trevi Therapeutics to Report Q1 2021 Financial Results on May 13
Conference Call and Webcast to be Held at 4:30 p.m. ET NEW HAVEN, Conn., May 6, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Conference Call and Webcast to be Held at 4:30 p.m. ET\n\n\nNEW HAVEN, Conn., May 6, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast on Thursday, May 13 at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2021. \n\n \n \n \n \n \n \n\n \nTrevi Therapeutics Hosting Conference Call on Q1 2021 Financial ResultsTo participate in the live conference call by phone, please dial (888) 317-6003 (domestic) or (412) 317-6061 (international) and provide access code 6116464. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event. \nAbout Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease and is in the planning stages of a Phase 2 study in this indication. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.\nFounded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.\nAbout HaduvioHaduvio, an investigational therapy, is an oral extended release formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement dis...